Mars will acquire US-based whole-fruit snacking brand Trü Frü to broaden its health and wellness portfolio.
Tru Fru will operate as an independent business and continue to be led by CEO, Brian Neville.
According to Neville, Mars shares a passion for healthier snacking and has the capabilities to take their company to the next level.
The transaction is subject to customary regulatory approvals and is expected to close in the first quarter of 2023.
Headquartered in West Valley City, Utah, with approximately 50 employees,
Trü Frü’s snacks are available in frozen and shelf-stable formats in US retailers.
Andrew Clarke noted that Trü Frü is a perfect complementary fit for their health and wellness portfolio, and their capabilities will help the brand strengthen its operations, broaden distribution and accelerate growth.
He added that Mars wants to be the preferred home for emerging and founder-led brands like Trü Frü.


Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
European Stocks Flat as Oil Prices Rise, US CPI in Focus
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data
Can your cat recognise you by scent? New study shows it’s likely
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility?
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



